Freitas Ana Julia Aguiar de, Causin Rhafaela Lima, Varuzza Muriele Bertagna, Hidalgo Filho Cassio Murilo Trovo, Silva Vinicius Duval da, Souza Cristiano de Pádua, Marques Márcia Maria Chiquitelli
Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos 14784-400, SP, Brazil.
Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo 01246-000, SP, Brazil.
Cancers (Basel). 2021 Oct 31;13(21):5477. doi: 10.3390/cancers13215477.
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new "OMICS" technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.
新辅助化疗（NAC）常用于治疗局部晚期疾病以实现肿瘤降期，从而提高保乳手术的几率。从NAC反应中，可以获得预后信息，因为患者可能达到病理完全缓解（pCR）。达到pCR的患者在生存率方面可能具有显著优势。乳腺癌（BC）是一种异质性疾病，需要个性化的治疗策略。靶向治疗的发展依赖于识别可用于评估治疗效果的生物标志物以及发现新的、更准确的治疗药物。随着新的“组学”技术（即基因组学、转录组学和蛋白质组学等）的发展，新生物标志物的发现越来越多地应用于临床实践中，使我们更接近BC治疗的个性化管理。本综述的目的是汇总预测BC患者NAC后pCR的主要生物标志物。
